Clinic
Fort Healthcare, INC.
Fort Healthcare, INC. was paid $9.44M by Medicaid between Jan 2018 and Dec 2024, across 237 billing codes. Its largest line is 99283, emergency room visit (moderate) — 8.5% of everything it billed.
33Billing provider infoFORT HEALTHCARE, INC.
FORT ATKINSON, WI 53538
FORT ATKINSON, WI 53538
33aNPI1811916281assigned 07/18/2006
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$9.44M
24GClaims524,322
24DCodes billed237
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Wisconsin
Rank by total paid#6 of 40
Median peer was paid$333K
This provider vs. median28×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 60,450 | $991K | |
| 2019 | 60,091 | $998K | |
| 2020 | 63,036 | $1.09M | |
| 2021 | 85,637 | $1.46M | |
| 2022 | 92,373 | $1.66M | |
| 2023 | 93,173 | $1.73M | |
| 2024incomplete | 69,562 | $1.52M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.5% | 14,014 | 12,327 | $804K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.0% | 12,418 | 10,773 | $755K |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.3% | 6,860 | 4,635 | $597K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.1% | 12,494 | 10,719 | $577K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.9% | 16,138 | 5,294 | $364K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.1% | 7,883 | 6,555 | $297K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.0% | 2,350 | 2,122 | $279K |
| 80053 | Comprehensive metabolic panel | 2.8% | 23,554 | 18,889 | $267K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.8% | 5,155 | 4,469 | $267K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 26,810 | 20,158 | $253K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 5,559 | 3,183 | $222K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.2% | 3,061 | 2,750 | $209K |
225 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 2,679 | $187K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 2,719 | $177K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.8% | 8,857 | $169K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 2,956 | $169K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 3,719 | $166K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.7% | 4,626 | $162K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.5% | 4,628 | $146K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.4% | 488 | $129K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.3% | 1,911 | $125K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.2% | 2,132 | $110K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 2,388 | $107K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 1,769 | $95K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,382 | $93K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,403 | $81K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,501 | $81K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 757 | $81K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,064 | $80K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,230 | $80K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 848 | $78K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,987 | $76K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,645 | $73K |
| 81025 | <1% | 7,389 | $73K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,966 | $71K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,472 | $70K |
| 81001 | <1% | 13,790 | $68K | |
| 80061 | Lipid panel | <1% | 5,410 | $62K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,426 | $62K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 702 | $54K |
| 87081 | <1% | 3,747 | $47K | |
| 97162 | <1% | 1,704 | $46K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 827 | $45K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,674 | $44K |
| 80050 | General health panel | <1% | 2,099 | $43K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,297 | $41K |
| 84484 | <1% | 6,823 | $40K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,558 | $40K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 90 | $40K |
| 80081 | <1% | 606 | $39K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 713 | $39K |
| 87186 | <1% | 3,949 | $36K | |
| 80306 | <1% | 2,525 | $34K | |
| 59025 | Fetal non-stress test | <1% | 597 | $33K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 445 | $33K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,943 | $32K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,027 | $32K |
| 88142 | <1% | 1,855 | $31K | |
| 82962 | <1% | 7,727 | $30K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,326 | $29K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,731 | $29K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 818 | $28K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 420 | $27K |
| 83880 | <1% | 1,902 | $27K | |
| 83690 | <1% | 5,370 | $26K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 516 | $24K |
| 76830 | Ultrasound, transvaginal | <1% | 708 | $24K |
| 87631 | <1% | 155 | $23K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 786 | $23K |
| 87040 | <1% | 2,552 | $21K | |
| 83605 | <1% | 4,008 | $20K | |
| 83735 | <1% | 4,477 | $20K | |
| 87503 | <1% | 704 | $20K | |
| 93356 | <1% | 235 | $19K | |
| 87070 | <1% | 2,500 | $19K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,172 | $19K |
| 86803 | <1% | 1,596 | $19K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 386 | $16K |
| 83655 | <1% | 1,412 | $16K | |
| 84702 | <1% | 937 | $16K | |
| 85027 | <1% | 2,730 | $16K | |
| 76857 | <1% | 315 | $15K | |
| 85610 | <1% | 3,363 | $15K | |
| 85379 | <1% | 1,180 | $15K | |
| 96367 | <1% | 504 | $14K | |
| G0378 | Hospital observation service, per hour | <1% | 3,704 | $14K |
| 81002 | <1% | 1,110 | $14K | |
| 87205 | <1% | 2,000 | $14K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,146 | $13K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 208 | $13K |
| 97163 | <1% | 428 | $12K | |
| 87507 | <1% | 37 | $12K | |
| 87088 | <1% | 2,352 | $11K | |
| 74018 | <1% | 646 | $10K | |
| 84145 | <1% | 947 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 359 | $10K |
| 85018 | <1% | 2,509 | $9K | |
| 82803 | <1% | 706 | $9K | |
| 86140 | <1% | 1,465 | $8K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 105 | $8K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 221 | $7K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 13 | $7K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 279 | $7K |
| 97597 | <1% | 352 | $7K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 170 | $6K |
| 97166 | <1% | 223 | $6K | |
| 82728 | <1% | 655 | $6K | |
| 73630 | <1% | 1,212 | $6K | |
| 82607 | <1% | 495 | $5K | |
| 81003 | <1% | 2,564 | $5K | |
| 84439 | <1% | 559 | $5K | |
| 82570 | <1% | 1,154 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,568 | $4K |
| 73564 | <1% | 880 | $4K | |
| 85730 | <1% | 457 | $4K | |
| 86901 | <1% | 668 | $4K | |
| 87210 | <1% | 482 | $4K | |
| 87581 | <1% | 160 | $4K | |
| 87486 | <1% | 160 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,444 | $4K |
| 80164 | <1% | 197 | $4K | |
| 82950 | <1% | 765 | $4K | |
| 88720 | <1% | 43 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 468 | $3K |
| 73030 | <1% | 651 | $3K | |
| 82043 | <1% | 711 | $3K | |
| 97116 | <1% | 231 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 33,335 | $3K |
| 84153 | <1% | 218 | $3K | |
| 93971 | <1% | 88 | $3K | |
| 83540 | <1% | 567 | $3K | |
| 80076 | <1% | 362 | $3K | |
| 93976 | <1% | 91 | $3K | |
| 87561 | <1% | 88 | $3K | |
| 73610 | <1% | 935 | $2K | |
| 87147 | <1% | 402 | $2K | |
| 86850 | <1% | 629 | $2K | |
| 86780 | <1% | 207 | $2K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 24 | $2K |
| 87077 | <1% | 417 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 47 | $2K |
| 71250 | <1% | 59 | $2K | |
| 85014 | <1% | 888 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,856 | $2K |
| 82465 | <1% | 245 | $2K | |
| 85651 | <1% | 591 | $2K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $2K |
| 73110 | <1% | 442 | $1K | |
| 73130 | <1% | 461 | $1K | |
| 86900 | <1% | 673 | $1K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 32 | $1K |
| 12001 | <1% | 12 | $1K | |
| 70486 | <1% | 42 | $1K | |
| 76642 | <1% | 17 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,261 | $1K |
| 70496 | <1% | 14 | $1K | |
| 82565 | <1% | 275 | $1K | |
| 82105 | <1% | 62 | $914.60 | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 16 | $904.35 |
| 73502 | <1% | 238 | $896.71 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 29 | $896.71 |
| 72100 | <1% | 77 | $785.18 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 269 | $747.22 |
| 85652 | <1% | 259 | $668.13 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 881 | $660.64 |
| 82550 | <1% | 198 | $614.69 | |
| 76770 | <1% | 13 | $612.46 | |
| 76000 | <1% | 170 | $594.34 | |
| 87340 | <1% | 62 | $591.52 | |
| 99152 | <1% | 280 | $586.85 | |
| 76801 | <1% | 33 | $548.10 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,389 | $515.35 |
| 87641 | <1% | 44 | $463.85 | |
| 82746 | <1% | 37 | $413.94 | |
| 73080 | <1% | 43 | $405.03 | |
| 0064A | <1% | 35 | $368.34 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 23 | $286.68 |
| 0352U | <1% | 281 | $283.27 | |
| 90715 | <1% | 57 | $282.51 | |
| 84403 | <1% | 12 | $280.47 | |
| 96376 | <1% | 2,728 | $275.79 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 199 | $266.44 |
| 73140 | <1% | 41 | $262.40 | |
| 92557 | <1% | 13 | $211.49 | |
| 88342 | <1% | 39 | $204.44 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 14 | $169.45 |
| 82947 | <1% | 33 | $112.59 | |
| 36416 | <1% | 4,947 | $74.34 | |
| 84132 | <1% | 14 | $53.48 | |
| 93041 | <1% | 546 | $51.65 | |
| 90686 | <1% | 50 | $38.90 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,990 | $35.16 |
| 73562 | <1% | 12 | $34.22 | |
| A9270 | Non-covered item or service | <1% | 17,600 | $28.73 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 371 | $18.82 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 59 | $13.25 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,143 | $7.52 |
| J2704 | Injection, propofol, 10 mg | <1% | 186 | $4.56 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,967 | $4.28 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,077 | $3.29 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,014 | $2.43 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,749 | $1.87 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 963 | $1.71 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 548 | $1.62 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,218 | $1.56 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 330 | $1.40 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 609 | $0.77 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 238 | $0.50 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,268 | $0.24 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 577 | $0.13 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,747 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 1,343 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 25 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,827 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 194 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 316 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 233 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 95 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 45 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 15 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 27 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 16 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 57 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 129 | $0.00 |
| 51798 | 0% | 14 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 90 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 91 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 285 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 30 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 236 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 17 | $0.00 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 72 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 16 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 51 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 312 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 28 | $0.00 |
| S9443 | Lactation classes, non-physician provider, per session | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNELSON, JAMES (VP FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Acr Homes, INC. | Roseville, MN | $156.04M |
| Dayton Pediatrics P C | Dayton, TN | $3.09M |
| Huron Eye Clinic PC | Huron, SD | $1.17M |
| Vi Neurological Medical Group INC. | St Thomas, VI | $771K |
| Nadaburg Elementary District | Wittmann, AZ | $174K |
| Rickman Family Medical Clinic | Rickman, TN | $79K |
| Monroe County Health Center, Board of Trustees | Peterstown, WV | $53K |
| Nelson Clinic and Rehabilitation Care PA | Willmar, MN | $44K |
| Nelson Family Dentistry General Partnership Dba Polished Dental | Bismarck, ND | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.